ADVISORY: Nektar Sets Date and Conference Call for First Quarter 2004.Business Editors SAN CARLOS San Carlos (săn kär`lōs), residential city (1990 pop. 26,167), San Mateo co., W Calif.; inc. 1925. The chief manufactures are plastic products, hardware, and machine parts. , Calif.--(BUSINESS WIRE)--April 21, 2004 Nektar Therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. (Nasdaq:NKTR) will announce its financial results for the first quarter ended March 31, 2004 on Wednesday, May 5, 2004. On that day, Ajit Gill gill, in weights and measures gill, in weights and measures: see English units of measurement. , Nektar president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , will host a conference call for analysts and investors beginning at 2:00 p.m. Pacific Time, to discuss further the company's performance. Investors can access a live audio-only Webcast through a link that will be posted on the Investor Relations Investor relations The process by which the corporation communicates with its investors. section at Nektar's Web site at http://www.nektar.com. The Web broadcast of the conference call will be available for replay through May 19, 2004. Analysts and investors can also access the conference call live via telephone by dialing (800) 559-2403 (US); (847) 619-6534 (international). The passcode is Nektar and the leader is Mr. Ajit Gill. An audio replay will be available shortly following the call through May 19, 2004 and can be accessed by dialing (877) 213-9653 (U.S.) or (630) 652-3041(international) with a passcode of 8892347. Nektar Therapeutics, formerly Inhale in·hale v. 1. To breathe in; inspire. 2. To draw something such as smoke or a medicinal mist into the lungs by breathing; inspire. Therapeutic Systems, Inc., enables the development of differentiated, high-value therapeutics based on its leading drug delivery technologies. Nektar's expanded technology and development expertise allow it to develop and offer to partners new product opportunities, solve more development challenges, and realize the full potential of their therapeutics from new molecule entities to life-cycle management products. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion